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Background: This study aims to investigate the anti-inflammatory effect of biologically active phospholipids (BAP)
used in preparations for clinical practice in humans. Until date, except anti-neoplastic ability, little is known about
anti-inflammatory property of the phospholipids.
Methods: While the course of bacterially induced acute pneumonia and markers of inflammation were studied in
in vivo system in pigs orally supplemented with BAP, the pro- and anti-inflammatory response of
lipopolysaccharide-stimulated porcine monocyte-derived macrophages to 24 h- and 48 h-treatmeant by BAP was
investigated in in vitro system. In vivo, the animal health status was monitored and pro-inflammatory IL-1β and IL-8
in sera were detected by ELISA during the experiment, while bronchoalveolar lavage fluids (BALF) and the lungs
were examined post-mortem. Total and differential counts of white blood cell (WBC) were determined in blood
and BALF. In vitro, mRNA expression of pro-inflammatory (TNF-α, IL-1β, CXCL10) and anti-inflammatory (IL-10 and
Arg1) cytokines, and level of activated caspase 1 and phosphorylated protein kinase C epsilon (pPKCε), were studied
using qRT-PCR and Western blot, respectively. For the purposes of both systems, 6 animals were used in each of
the BAP-supplemented and the control groups.
Results: In vivo, BAP had a positive influence on the course of the disease. The immunomodulatory effects of BAP
were confirmed by lower levels of IL-1β, IL-8, and a lower WBC count in the supplemented group in comparison
with the control group. A lower percentage of lung parenchyma was affected in the supplemented group comparing
to the control group (on average, 4% and 34% of tissue, respectively). In vitro, BAP suppressed mRNA expression of
mRNA for IL-10 and all pro-inflammatory cytokines tested. This down-regulation was dose- and time-dependent. Arg1
mRNA expression remained unaffected. Further dose- and time-dependent suppression of the activated caspase 1 and
pPKCε was detected in macrophages when treated with BAP.
Conclusions: Our results demonstrate that BAP has anti-inflammatory and immunomodulatory properties,
thus emphasizing the potential of this compound as a natural healing agent.
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Ether phospholipids (EP) are important constituents of
eukaryotic cell membranes and energy reservoir, partici-
pating in cell signalling events [1]. The activity of EP
leading to the selective destruction of neoplastic cell
membranes has been shown in numerous publications
over the last decades [2-10] and thus represents a prom-
ising tool for cancer therapy for humans. A membrane-
tropic mechanism of EP was reported to play a key role
in the destruction of neoplastic cell membranes resulting
in cell death [11] and the importance of plasma mem-
brane fluidity modulation by lipid membrane compos-
ition was presented [12-14]. Moreover, the cytotoxic
effect of EP could partially be due to the inhibition of
protein kinase C (PKC) or other membrane–associated
enzymes [9,15,16], which play central roles in cellular
signal processing and are involved in the regulation of
cell proliferation and migration. PKC was also demon-
strated to be an important signalling molecule in cancer
invasiveness and metastasis [17,18]. Considering HeLa
cells under physiological conditions, only PKC isoform ε
was shown to be responsible for their spreading [19].
However, a disadvantage of EP application for human
cancer therapy is that most of them are synthetic prepa-
rations associated with toxic side effects (such as a
membrane destruction of normal, i.e. non neoplastic,
cells) limiting their clinical use [3,7].
A natural mixture of EP prepared from ischemic chick
embryonic tissue and described by Kára and coworkers
[20] was proved to suppress proliferation and growth of
malignant cells with sparing normal physiological cells.
This discovery has recently resulted in registration of a
unique mixture of biologically active phospholipids
(BAF®) (Areko, Inc., Prague, CZ), which is the substantial
active component of a commercial pharmaceutical diet-
ary supplement. In accordance with the secret manufac-
turing process, the exact composition of the mixture
cannot be provided. However, it can be affirmed that the
natural EP 1-O-octadecyl-2oleoyl-sn-glycero-3phospho-
(N-palmitoyl) ethanolamine, i.e., plasmanyl-(N-acyl)-
ethanolamine (PNAE) [21], represents 30% of the
mixture. A PNAE analogue was semisynthetically pre-
pared [22] and its inhibiting effect on PKC which is of
high importance in cancer cell proliferation was estab-
lished [15]. Both EP, natural and synthetic, have been
widely investigated for their selective antineoplastic
activity without a toxic effect on normal cells in
biological systems in vitro and in vivo [7,14,23,24].
Another essential component of BAF® is egg phosphat-
idylcholine (PC) (60%) – one of the major phospho-
lipids in lecithin. PC is known to be the most abundant
phospholipid component in eukaryotic cells, being
spontaneously organized into bilayers in the outer leaf-
let of the cell membrane [1].The aim of this study was to assess the expected anti-
inflammatory activity of BAP on the course of experi-
mental infection with Actinobacillus pleuropneumoniae
(App) in pigs. The activity of BAP was also assessed
in vitro by evaluating the intensity of inflammatory reac-





A total of 12 piglets included in the study (5 weeks old,
average body weight 10–12 kg) were allocated into two
groups of 6 animals each. The piglets originated from a
herd which was free of clinical App infection for at least
12 months. Neither the piglets nor their mothers were
vaccinated against App and the results of anti-App anti-
body detection in piglet sera by ELISA method [25] were
negative.
Supplementation regime and experimental Actinobacillus
pleuropneumoniae infection
Animals in experimental group were given a 15% solu-
tion of BAP in sunflower oil in a dietary supplement
Ovosan (Areko, Inc., Prague, Czech Republic, approxi-
mately 75 mg/kg of b.w.). Animals in control group were
given pure sunflower oil orally using a syringe, in a vol-
ume of 5 ml per animal twice daily for a period of
28 days, with the same time and dosage regime. Four-
teen days after the start of the administration of BAP or
pure oil, all animals were experimentally infected with
3 ml of the bacterium App via the intranasal route
(1.5 ml was administered into each nostril). The field
strain KL2–2000, biotype 1, serotype 9 was used at the
final concentration of the infectious dose of 4.4 ×
108 CFU/ml [26].
Phospholipids
Phospholipids (PLs) constituting the BAP preparation
were extracted from hen egg yolk with ethanol and puri-
fied using acetone precipitation according to standard
procedures [27]. BAP preparation was enriched to final
concentration 30% with 1-O-octadecyl-2oleoyl-sn-gly-
cero-3phospho-(N-palmitoyl) ethanolamine as described
earlier [21,28]. BAP preparation was provided by com-
pany Areko, Inc., Prague, Czech Republic.
Parameters of animal health status investigated during
the experiment
The health status of animals was monitored during the
entire experiment. Body temperature was taken in the
rectum of animals at four clinically important time
points: one day before experimental exposure to the in-
fectious agent and at 1, 3 and 7 days post-infection (PI).
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respiration rate, dyspnea, cough, anorexia, lethargy, death)
were monitored and recorded twice a day.
Furthermore, peripheral blood samples were collected
for determination of total and differential counts of
WBC and serological analyses [25] at six time points -
before the beginning of supplementation, immediately
before infection, and at days 1 (without App antibody
detection), 3, 7 and 14 post-infection (PI). Besides that,
at first four of these junctures, peripheral blood samples
were collected for the detection of acute phase cytokines
(interleukins 1β and 8) using a commercially available
ELISA kit (Alpco Diagnostic, Salem, NH) in accordance
to manufacturer’s recommendation. After completing
the experiment (at 2 weeks PI), animals were weighed,
euthanized with the intravenous application of anaes-
thetic T61 (Intervet International B.V., Boxmeer, the
Netherland) on the basis of the actual body weight of an
animal according to the manufacturer’s recommenda-
tions (5 ml/50 kg of body weight), and necropsied. The
status of the lung parenchyma was assessed at necropsy
and pulmonary scores documenting the extent of pul-
monary parenchymal damage were calculated [26]. At
the same time, bronchoalveolar lavage fluids (BALF)
were collected for serological analysis and cytology of
cell infiltrate [29].
Animal welfare treatment
Animal experiments complied with Act No. 246/92 Sb.
and were approved by the Branch Commission for Ani-
mal Welfare of the Ministry of Agriculture of the Czech
Republic (No. 25–2009; Reg. No. 1092). Experiments
were conducted in accredited special barrier facilities for
animal housing at the Veterinary Research Institute
(Accreditation No. 5843/2007-10001). Animal cadavers
were disposed of in compliance with the Rules for




A mononuclear fraction of white blood cells (WBC) was
isolated from the whole heparinized blood from 6
healthy adult pigs using a density gradient technique
(Histopaque 1.077, Sigma-Aldrich, St. Louis, MO). Sub-
sequently, a CD14-positive cell subset was selected
by indirect magnetic labeling on QuadroMACS™ cell
separator (Miltenyi Biotec, Gladbach, Germany) using
monoclonal antibody against CD14 (clone MIL2, AbD
Serotec, Oxford, UK, 10 μl per 108 cells). CD14-positive
cells were captured by goat anti-mouse IgG MicroBeads
(Miltenyi Biotec, Gladbach, Germany). The cell subset
purity was assessed using flow cytometer LSRFortes-
saTM (BD Biosciences, San Jose, CA) and was morethan 95% in all cases. CD14-positive monocytes, ap-
proximately 0.5 × 106 cells per well in 24-well plates,
were cultured in Dulbecco’s Modified Eagle’s Medium
(Invitrogen, Paisley, UK) supplemented with antibiotics
(100,000 IU/l penicillin; 10 mg/l streptomycin; 4 mg/l
gentamicin) and 10% (v/v) heat-inactivated porcine
serum (PAA Laboratories, Pashing, Austria) at 37°C in
an atmosphere with 5% (v/v) CO2. After 6 days of culti-
vation, monocyte-derived macrophages (MDMF) were
prepared [30].
Cell viability determination
The activity of a cytoplasmic enzyme lactate dehydro-
genase (LDH), actually its outflow into extracellular
space, was monitored. LDH accumulated in culture
medium, indicative of increased plasma membrane dam-
age, correlating with the increase in the number of lysed
cells, was measured using CytoTox 96® Non-Radioactive
Cytotoxicity Assay (Promega, Madison, WI) following
the manufacturer’s recommendations.
Design of culture experiment
The experimental conditions were arranged as follows:
cultures of MDMF were incubated with BAP at concen-
trations 0% (control), 0.03%, 0.1%, and 0.3% (i.e. 0.3; 1;
3 mg per ml of culture media, respectively) for 24 and
48 h. After one following washing step with the cultiva-
tion medium, one half of the cultures exposed to the in-
dicated concentrations of BAP was stimulated with
1 μg/ml of lipopolysaccharide (LPS) for 4 hours. After-
wards, the supernatants were removed by aspiration and
the adhered cells were lysed in TRI Reagent RT (Mo-
lecular Research Center, Inc., Cincinnati, OH) or in 1x
Laemmli buffer (0.5 M Tris–HCl pH 6.8, glycerol, 10%
SDS, bromophenol blue, beta-mercaptoethanol, deion-
ized water) for RNA and protein extraction, respectively.
RNA preparation and quantitative PCR analysis
Total RNA with elution volume of 15 μl was obtained
using the combination of 4-Bromoanisole phase separ-
ation followed by silica-based RNeasy purification (Qia-
gen, Hilden, Germany) according to the manufacturer’s
protocol. mRNA was specifically reverse-transcribed
using M-MLV reverse transcriptase system (Invitrogen,
Paisley, UK) in the presence of oligo-dT primer. cDNA
was diluted 5x and 0.5 μl used in qPCR. In qPCR ana-
lysis, RNA expression was quantified in triplicate reac-
tions in a final volume of 3 μl in 384-well plates using
QuantiTect SYBR Green PCR master mix (Qiagen,
Hilden, Germany) following the manufacturer’s recom-
mendations, on a LightCycler 480 (Roche Applied
Science, https://www.roche.com/). qPCR reactions were
prepared with the assistance of Nanodrop II liquid dis-
penser (Innovadyne Technologies, Rohnert Park, CA).
Vicenova et al. BMC Complementary and Alternative Medicine 2014, 14:339 Page 4 of 10
http://www.biomedcentral.com/1472-6882/14/339qPCR was performed under the following conditions:
denaturation (95°C for 15 min) and 45 amplification cy-
cles (95°C for 15 s, 58°C for 30 s and 72°C for 30 s).
Resulting melting curves were analyzed to test the prod-
uct specificity. Each couple of primers (Table 1, Generi
Biotech, Hradec Kralove, Czech Republic) at 10 pmol
was used per reaction. Primers specific to 5 target genes,
coding for cytokines with pro- and anti-inflammatory
properties, and 3 reference genes were used for simul-
taneous measurements of gene expression activity.
Among the candidate reference genes, TBP-1 was evalu-
ated as the most constitutively expressed gene in our
samples using RefFinder tool (http://www.leonxie.com/
referencegene.php) and was selected to adjust mRNA
measurements. From the obtained data, relative expres-
sion of each target gene was calculated according to the
formula [1/(2target gene Ct)]/[1/(2reference gene Ct)] [36].
Western blot
Intracellular activation of caspase 1 and phosphorylation
of PKCε, enzymes involved in the signalling pathways
mediating inflammatory responses, were under investi-
gation. Cell suspensions with extraction lysis buffer were
subjected to 2 - 5 min incubation in boiling water followed
by short freezing. Cellular proteins of processed cell ex-
tracts were separated on a 10% SDS-polyacrylamide gel
electrophoresis and transferred onto PVDF (polyvinyli-
dene difluoride) membrane. The blot was incubated in a
blocking reagent (5% low-fat dry milk suspended in wash
buffer containing 2 M Tris pH7.6, NaCl, 10% Tween 20,Table 1 Gene specific primers used to assess the anti-inflamm

















aLAF = Lymphocyte-activating factor, bTNFSF2 = TNF ligand superfamily member 2,
growth factor. F = Forward primer, R = Reverse primer.deionized water) at room temperature for 1 hour, followed
by another 1 hour incubation with specific primary
polyclonal antibodies: caspase 1 (diluted 1:500; Acris
Antibodies, San Diego, CA, USA), phosphorylated PKCε
(pPKCε; Ser729, diluted 1:500; Santa Cruz Biotechnology,
Inc., Heidelberg, Germany) and PKCε (diluted 1:1000;
Santa Cruz Biotechnology, Inc., Heidelberg, Germany),
while anti-β actin mouse monoclonal antibody (diluted
1:5,000; IgG1, clone AC-15; Abcam, Cambridge, UK) was
included as a loading control. Blots were washed 3 - 4
times in wash buffer and secondary antibodies donkey
anti-mouse IgG (diluted 1:10,000; Jackson Immuno Re-
search, West Grove, PA, USA) and goat anti-rabbit IgG
(diluted 1:5,000; Jackson Immuno Research, West Grove,
PA, USA) applied for 1 hour at room temperature. After
3 – 4 final washing steps, proteins were visualized by using
ECL Western Blotting Substrate (GE Healthcare Life
Sciences, Buckinghamshire, UK).Statistical methods
Statistical evaluation of data obtained by serological
examination and differences in the pulmonary scores
was carried out by the unpaired non-parametric Mann–
Whitney U test while the PCR results were statistically
evaluated by the paired non-parametric Friedman with
Dunn’s post test using GraphPad Software Prism 3.03
[37]. P values of less than 0.05 were considered statisti-
cally significant. Results are presented as the mean







Reference gene, RNApolymerase II transcription
initiation/[35]
Reference gene, heme biosynthesis/[35]
Reference gene, purine ribonucleoside salvage/[36]
AA
cIP10 = Interferon gamma-induced protein 10, dB-TCGF = B-cell derived T-cell
Figure 1 Body temperature of pigs supplemented and
non-supplemented with biologically active phospholipids after
experimental infection by Actinobacillus pleuropneumoniae.
The data represent mean ± standard deviation of values of six
animals per group. Statistical difference between groups was
depicted *(p < 0.05).
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ment, respectively.Results
In vivo anti-inflammatory effect
Effect of BAP on the clinical course of pneumonia in pigs
Experimental challenge exposure to App induced infec-
tion in all pigs, but between-group differences were ob-
served in the clinical course of infection. The animals in
control group showed an increase in the respiratory rate,
dyspnoea and incipient mild cough after 6–10 h PI. All 6
animals displayed increased body temperature (Figure 1),
which was slowly decreasing, and remained above the
physiological range in two animals after a week of infec-
tion. Comparable clinical signs were observed in supple-
mented group after 6–10 h PI. However, they resolved
on day 2 PI (Figure 1).Table 2 Effect of BAF on WBC count and differential in periph
WBC (x 106 in ml) Lymphocy
Control Supplemented Control
Day −14 16.5 ± 2.1 18.5 ± 4.4 66.9 ± 9.7
Day 0 18.0 ± 3.2 20.1 ± 2.5 57.6 ± 7.5
Day 1 24.6 ± 6.3 21.1 ± 6.5 45.2 ± 10.8
Day 3 20.9 ± 6.0 21.5 ± 4.0 50.9 ± 12.9
Day 7 19.2 ± 4.1 15.6 ± 2.7 54.6 ± 16.0
Day 14 15.4 ± 4.4 10.6 ± 1.3 56.3 ± 18.9
Day −14 = beginning of BAF supplementation. Day 0 – App challenge.
Values represent mean ± S.D., n = 6 animals in each group.Effect of BAP on white blood cell counts in blood
As shown in Table 2, supplementation of animals with
BAP before the infection did not lead to statistically sig-
nificant changes in either total counts of WBC or per-
centages of lymphocytes and neutrophils. Increased
WBC counts were detected in blood of all animals after
the infection. In control group, the increase was signifi-
cant (from on average 18.0 to 24.6 × 106/ml, p < 0.05).
Contrary to that, the increase was non-significant in the
case of supplemented animals (from on average 20.1 to
21.1 × 106/ml, p > 0.05). The same manner was true also
for the increase and decrease of neutrophil and lympho-
cyte percentage, respectively. In control animals, these
changes were significant (p < 0.05) in both parameters.
In supplemented animals, both changes were non-
significant (p > 0.05).
Effect of BAP on white blood cell counts in
bronchoalveolar lavage fluid
In BALF samples from the respiratory tract of healthy
pigs, normal WBC counts are in the range of 0.8–5 × 106/
ml. As expected, counts of WBC in our experiment were
higher in both groups than normal values. The counts
achieved 11.7 ± 6.1 and 6.4 ± 4.2 × 106/ml (p < 0.05) in ani-
mals from control and supplemented group, respectively.
While in healthy BALF macrophages represent 85–98%
of WBC, in our experiment, these percentages dropped to
62.5 ± 13.5 and 62.7 ± 19.5 (p > 0.05) in animals from con-
trol and supplemented group, respectively. Percentage of
lymphocytes increased from normal 5–10% up to 14.5 ±
6.3 and 16.6 ± 5.1 (p > 0.05) in animals from control and
supplemented group, respectively. The most marked
changes when compared to normal 0–5% were detected in
percentage of neutrophils. Their percentages increased up
to 22.7 ± 14.2 and 20.9 ± 10.6 (p > 0.05) in animals from
control and supplemented group, respectively.
Effect of BAP on serological parameters and cytokines
Levels of App-specific serum IgM and IgG antibodies
and local IgA and IgG antibodies in BALF wereeral blood
tes (%) Neutrophils (%)
Supplemented Control Supplemented
62.8 ± 15.8 31.2 ± 9.8 35.8 ± 9.9
58.8 ± 8.4 39.7 ± 8.1 39.4 ± 8.1
47.7 ± 11.9 52.5 ± 11.5 50.0 ± 13.1
43.1 ± 8.8 46.7 ± 13.2 55.0 ± 9.2
52.9 ± 7.8 42.8 ± 15.9 45.5 ± 8.6
64.6 ± 8.0 43.2 ± 19.1 34.4 ± 8.5
Figure 2 Actinobacillus pleuropneumoniae-specific antibodies in pigs supplemented and non-supplemented with biologically active
phospholipids after experimental infection by Actinobacillus pleuropneumoniae. Dynamics of IgM (A) and IgG (B) in serum, and levels of
IgA (C) and IgG (D) in bronchoalveolar lavage fluid 14 days post-infection. The data are expressed as mean ± standard deviation of values of six
animals per group.
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caused a typical primary immune response in the blood
of pigs of both groups, a rapid onset of production of
system IgM antibodies followed by production of IgG
antibodies. Nonsignificantly higher levels of antibodies
were observed in the control group. The examinationFigure 3 Illustrative picture of lungs of pigs supplemented and non-s
challenge by Actinobacillus pleuropneumoniae. Lungs with pathological
whereas no significant changes were seen in lungs of pigs from supplemeof BALF revealed that the infection elicited IgA anti-
body production in the respiratory tract mucosa, be-
ing nonsignificantly higher in supplemented animals.
Furthermore, a statistically nonsignificant elevation
of IgG antibodies was detected in BALF in the con-
trol group.upplemented with biologically active phospholipids 14 days after
changes (left picture) were seen in pigs of non-supplemented group,
nted group (right picture).
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tectable production of cytokine IL-1β on day 1 PI,
whereas supplemented animals did not respond to BAP
at all (data not shown). No elevation of cytokine IL-8
level occurred in any of the animals in both groups
tested.
Effect of BAP on porcine pulmonary parenchyma
examined post-mortem
Post-mortem examination of the pulmonary parenchyma
showed a significant difference in resistance to App be-
tween the supplemented and the control group, with the
percentage of inflamed tissue being 4% and 34%, respect-
ively. The occurrence of pulmonary parenchymal lesions
in the control group was chronic in nature. Necrotic-
fibrinous pneumonia was diagnosed, which either was orFigure 4 Transcription activity of genes regulating inflammatory p
LPS-stimulation in vitro. The expression activity of pro-inflammatory g
IL-10 (D) and Arg1 (E) was influenced by concentration of biologically a
expressed as a percentage of the control (without biologically active ph
and nonstimulated macrophages. Values are expressed as median ± max
treatments and control was depicted *(p < 0.05).was not associated with pleurisy and pericarditis. Figure 3
shows significant differences between the lungs of pigs
in the two tested groups.
In vitro anti-inflammatory effect
Effect of BAP on LPS-induced gene expressions in
monocyte-derived macrophages
To investigate the anti-inflammatory effect of BAP at
the cellular level, the transcriptional activity of cytokine
genes with pro-inflammatory (TNF-α, IL-1β, CXCL10)
and anti-inflammatory (IL-10 and Arg1) properties in-
duced by LPS in MDMF was evaluated. The results of
this study showed that despite great individual differ-
ences, BAP is able to influence the immune response of
macrophages. This influence was effectively expressed as
a percentage of the decrease/increase (compared withrocesses in porcine monocyte-derived macrophages after
enes TNF-α (A), IL-1β (B), CXCL10 (C) and anti-inflammatory genes
ctive phospholipids and the time of action. This influence was
ospholipids) in the ratio of transcriptional activity in LPS-stimulated
imum and minimum of hexaplicates. Statistical difference between
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LPS-stimulated and nonstimulated macrophages. Their
incubation with BAP led to suppression of the expression
levels of pro-inflammatory cytokines and IL-10. Dose-
dependent statistically significant and time-dependent ex-
pression level decrease was observed. On the contrary,
Arg1 expression level was either upregulated or – in case
that BAP concentrations were higher - remained the same
(Figure 4).
Effect of BAP on the LPS-induced activation of caspase 1
and pPKCε in monocyte-derived macrophages
Similarly, it was found that BAP downregulated procas-
pase 1 fragmentation, and consequently formation of ac-
tive caspase 1 after LPS treatment, depending on BAP
concentration and the time of incubation. A similar ef-
fect of BAF was also detected in the case of PKCε phos-
phorylation (Figure 5). A higher anti-inflammatory effect
of BAP was observed after 48 h of incubation.
Discussion
The ability of EP to inhibit or prevent the growth and
spread of tumours has been shown in many studies
[3,6,9,23,38]. Even so, the exact mechanism of action
leading to suppression of neoplastic cells has not been
completely clarified. Recently, it was proved that EP in
plasma membrane act on ion channels, modulate their
function [39], and consequently enhance calcium ion cellFigure 5 Downregulation of caspase-1 activation and PKCε
phosphorylation in porcine monocyte-derived macrophages
by biologically active phospholipids. The activation of caspase-1
and phosphorylation of PKCε decreased after 0.3% BAF incubation
comparing with control (without biologically active phospholipids) and
cells treated with lower concentrations (0.03% and 0.1%) of biologically
active phospholipids. A higher anti-inflammatory effect of biologically
active phospholipids was observed after 48 h of BAF incubation. β-actin
served as loading control.concentration altering cell membrane permeability fi-
nally leading to death of tumour cell [23]. Contrary to
this finding, the inflammatory response of the host im-
mune system to bacterial infection or tissue injury can
trigger or accelerate a neoplastic process [40]. Therefore,
safe compounds with the anti-inflammatory potential
are needed in therapeutic treatment and prophylaxis of
inflammation-related diseases including atherosclerosis,
inflammatory arthritis and even neoplasm. The reducing
effect of natural compounds on inflammation by sup-
pression of inflammatory cytokines in vivo and in vitro
applicable in such cases has been described [40-43].
However, the effect of EP on the immune system re-
sponse has not been well studied yet. The immunosti-
mulatory and regenerative effects of derivatives of EP on
the immune system were demonstrated in studies, in
which mice [44,45] and pigs [46] served as experimental
models. To the best of our knowledge, no previous stud-
ies have reported the transcription cell response to EP.
In the present study, porcine system was used for the
first time to evaluate the anti-inflammatory and immu-
nomodulatory response to BAP after App- or LPS-
activation of the immune system. In vivo, a milder
course of the disease and easy recovery of animals
showed a potent protective effect of BAP and indicated
the importance of BAP in inflammation development.
Furthermore, the parameters of the innate and adaptive
immune defence against the infection including neutro-
phils and macrophages as non-specific immune cells,
and specific immunity mediating antibodies and lym-
phocytes, confirmed the apparent protective potency of
the compound. Specifically, changes in total and differ-
ential counts of WBC and bronchoalveolar cytology
reflecting ongoing bacterial infection confirmed the
assumed immunomodulatory and anti-inflammatory
effect of BAP. BAP-supplementation led to a slight
increase in WBC count in the blood. Furthermore, the
investigated parameters more quickly returned to nor-
mal values due to BAP.
A similar boosting effect on WBC count, but statisti-
cally significant, was demonstrated by bronchoalveolar
lavage cytology, with considerable differences in lympho-
cyte and macrophage percentages between the tested
groups. This is in accordance with other authors who
observed an increased non-specific immune response
[46] in a bacterial stimulus free diet experiment, in
which choline based EP, soy or egg lecithin were orally
administered to weaned piglets. An increase of granulo-
cyte and decrease of lymphocyte percentages in blood
observed on day 11 of supplementation of each of the
lecithins were comparable to those obtained after
14 days of BAP-supplementation immediately before
infection. Moreover, the maximum immunomodula-
tory effects of choline- and BAP-based preparations on
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supplementation in each preparation tested were found
to be comparable, irrespective of the ongoing infection
in the BAP experiment. Furthermore, our serological
results showed that only pigs non-supplemented with
BAP responded by detectable IL-1β and IL-8 produc-
tion and thus confirmed the ability of BAP to inhibit
the inflammatory process. In supplemented pigs,
BAP also contributed, statistically significantly, to a
lower damage to the pulmonary parenchyma without
further complications than was observed in un-
affected pigs.
To verify anti-inflammatory potential of BAP in macro-
phage system, we further analysed gene expression profiles
of cytokines and elevation of other mediators involved in
the inflammatory process. Generally, the cytokine profiles
were in agreement with our previous findings. Macro-
phages clearly responded to the tested compound by
downregulation of expression of proinflammatory cyto-
kines. However, the effect of BAP on expression of anti-
inflammatory cytokines was not uniform. According to
established downregulation of IL-10 expression we can de-
duce that BAP tends to lead to homeostatic balance of
proinflammatory and anti-inflammatory cytokines, which
is crucial for maintaining health. On the other hand, ex-
pression of arginase, which was shown to participate in
inflammation-triggered immune dysfunctions, immuno-
suppression and immunopathology of infectious diseases,
was influenced rather positively by BAP treatment. Specif-
ically, arginase expression in macrophages is regulated by
different stimuli such as LPS, lipoproteins, inflammatory
stimuli and hydrogen peroxide in a species-specific way,
and the enzyme function in the immune system of
mammals except pigs has frequently been studied [47].
Similarly to EP capable to inhibit PKC [15,16], we dem-
onstrated the inhibition of phosphorylation of PKCε by
BAP. Also, downregulation of procaspase 1 fragmenta-
tion demonstrated here is in accordance with the afore-
mentioned results confirming the anti-inflammatory
potency of BAP.
Conclusion
In this study, under in vivo conditions, we detected anti-
inflammatory and immunomodulatory effects of BAP at
all levels investigated: health status, total and differential
counts of WBC, serological parameters, pro-inflammatory
cytokines, BALF and pulmonary parenchyma. Further-
more, BAP exerted anti-inflammatory activity in vitro
under controlled conditions of monocyte-derived macro-
phages stimulated with LPS. It manifested itself as modu-
lation of gene expression of cytokines and activation
enzymes playing an important role in the activation of
intracellular signalling pathways associated with the induc-
tion of inflammation.Competing interests
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